• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

FiercePharma: Leqembi launch hamstrung by physicians' 'therapeutic nihilism'


<











Dr. M****** G*******, a professor at Stanford University's Center for Memory Disorders, said there is little evidence that Leqembi benefits patients in a meaningful way.
 




Dr. M****** G*******, a professor at Stanford University's Center for Memory Disorders, said there is little evidence that Leqembi benefits patients in a meaningful way.

“If we take the trial result at face value, the differences between placebo and treatment are likely small enough as to be undetectable by patients and family members or physicians,” Michael Greicius, M.D., a professor at Stanford University's Center for Memory Disorders, said. Greicius doesn’t recommend Leqembi to patients.